Screening for potent and selective anticlostridial leads among FDA-approved drugs

[1]  M. Seleem,et al.  Chemical Space Exploration Around Thieno[3,2-d]pyrimidin-4(3H)-one Scaffold led to a Novel Class of Highly Active Clostridium difficile Inhibitors. , 2019, Journal of medicinal chemistry.

[2]  M. Seleem,et al.  Antibacterial and antivirulence activities of auranofin against Clostridium difficile. , 2019, International journal of antimicrobial agents.

[3]  K. Hevener,et al.  The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. , 2018, ACS infectious diseases.

[4]  M. Seleem,et al.  Repurposing ebselen for decolonization of vancomycin-resistant enterococci (VRE) , 2018, PloS one.

[5]  M. Seleem,et al.  Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci. , 2018, International journal of antimicrobial agents.

[6]  K. Carroll,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Mylonakis,et al.  Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori , 2018, Scientific Reports.

[8]  E. Kuijper,et al.  How to: Surveillance of Clostridium difficile infections. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  P. Nenoff,et al.  New insights on the antibacterial efficacy of miconazole in vitro , 2017, Mycoses (Berlin).

[10]  M. Cooper,et al.  Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases. , 2017, Journal of medicinal chemistry.

[11]  M. Seleem,et al.  In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens. , 2017, Current pharmaceutical design.

[12]  K. Janda,et al.  Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile , 2016, Scientific Reports.

[13]  A. Moya,et al.  Colonization Resistance of the Gut Microbiota against Clostridium difficile , 2015, Antibiotics.

[14]  M. Seleem,et al.  Repurposing celecoxib as a topical antimicrobial agent , 2015, Front. Microbiol..

[15]  M. Seleem,et al.  Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections , 2015, Scientific Reports.

[16]  M. Seleem,et al.  Drug repurposing for the treatment of staphylococcal infections. , 2015, Current pharmaceutical design.

[17]  Wooseong Kim,et al.  Repurposing Salicylanilide Anthelmintic Drugs to Combat Drug Resistant Staphylococcus aureus , 2015, PloS one.

[18]  M. Cooper,et al.  Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents , 2015, Journal of medicinal chemistry.

[19]  Lisa G Winston,et al.  Burden of Clostridium difficile Infection in the United States , 2015 .

[20]  S. Adhikari,et al.  Action of nitroheterocyclic drugs against Clostridium difficile. , 2014, International journal of antimicrobial agents.

[21]  D. Paredes-Sabja,et al.  Clostridium difficile spores: a major threat to the hospital environment. , 2014, Future microbiology.

[22]  Randhir Singh,et al.  Imidazoles as promising scaffolds for antibacterial activity: a review. , 2013, Mini-Reviews in Medical Chemistry.

[23]  Ashwin N Ananthakrishnan,et al.  Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections , 2013, The American Journal of Gastroenterology.

[24]  S. Mas‐Coma,et al.  Administration of Triclabendazole Is Safe and Effective in Controlling Fascioliasis in an Endemic Community of the Bolivian Altiplano , 2012, PLoS neglected tropical diseases.

[25]  M. Cruz.  Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults. , 2012, P & T : a peer-reviewed journal for formulary management.

[26]  A. Zinsmeister,et al.  The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study , 2012, The American Journal of Gastroenterology.

[27]  D. Musher,et al.  Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[29]  D. Farver,et al.  New advances in the treatment of Clostridium difficile infection (CDI) , 2008, Therapeutics and clinical risk management.

[30]  Matthew A. Croxen,et al.  Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori, Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuni , 2006, Antimicrobial Agents and Chemotherapy.

[31]  J. Gookin,et al.  Efficacy of Ronidazole for Treatment of Feline Tritrichomonas foetus Infection , 2006 .

[32]  P. Upcroft,et al.  5-Nitroimidazole Drugs Effective against Metronidazole-Resistant Trichomonas vaginalis and Giardia duodenalis , 2006, Antimicrobial Agents and Chemotherapy.

[33]  C. Janson,et al.  1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI). , 2001, Bioorganic & medicinal chemistry letters.

[34]  R. Rolfe,et al.  In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile , 2000, Antimicrobial Agents and Chemotherapy.

[35]  M. Ghannoum,et al.  Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance , 1999, Clinical Microbiology Reviews.

[36]  L. Jokipii,et al.  Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius , 1987, Antimicrobial Agents and Chemotherapy.

[37]  R. Bolton,et al.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. , 1986, Gut.

[38]  L. Jokipii,et al.  Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group , 1985, Antimicrobial Agents and Chemotherapy.

[39]  J. Wüst.  Susceptibility of Anaerobic Bacteria to Metronidazole, Ornidazole, and Tinidazole and Routine Susceptibility Testing by Standardized Methods , 1977, Antimicrobial Agents and Chemotherapy.

[40]  R. Willcox,et al.  Treatment of Vaginal Trichomoniasis with 2-Acetylamino-5-Nitrothiazole (Aminitrozole) given Orally* , 1957, The British journal of venereal diseases.

[41]  T. Hazbun,et al.  Ebselen exerts antifungal activity by regulating glutathione (GSH) and reactive oxygen species (ROS) production in fungal cells. , 2017, Biochimica et biophysica acta. General subjects.

[42]  M. Lesina,et al.  Use of Ronidazole and Limited Culling To Eliminate Tritrichomonas muris from Laboratory Mice. , 2016, Journal of the American Association for Laboratory Animal Science : JAALAS.

[43]  Waleed Younis,et al.  Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections. , 2015, Current pharmaceutical design.

[44]  W. Gregory,et al.  Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7 2007 , 2012 .

[45]  J. Gookin,et al.  Efficacy of ronidazole for treatment of feline Tritrichomonas foetus infection. , 2006, Journal of veterinary internal medicine.

[46]  D. V. van Thiel,et al.  The diagnosis and treatment of Clostridium difficile in antibiotic-associated diarrhea. , 1999, Hepato-gastroenterology.

[47]  N. N. Kalinichenko.  [Nitazole--an antimicrobial substance]. , 1998, Mikrobiolohichnyi zhurnal.

[48]  Kalinichenko Nf.  [Nitazole--an antimicrobial substance]. , 1998 .

[49]  R. Erkkola,et al.  Single dose of ornidazole in the treatment of bacterial vaginosis. , 1987, Annales chirurgiae et gynaecologiae. Supplementum.

[50]  G. Bonse,et al.  Chemistry of Anticestodal Agents , 1986 .